Correction: Differential inhibition of the TGF-β signaling pathway in HCC cells using the small molecule inhibitor LY2157299 and the D10 monoclonal antibody against TGF-β receptor type II (PLoS ONE) (PLoS ONE (2013) 8, 6 (e67109) DOI:10.1371/journal.pone.0067109);Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Dituri, Francesco ^a   Mazzocca, Antonio ^a   Peidrò, Fernando Juan ^b   Papappicco, Patrizia ^a   Fabregat, Isabel ^b   De Santis, Flavia ^a   Paradiso, Angelo ^c   Sabbà, Carlo ^a   Giannelli, Gianluigi ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^c NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; FIBRINOGEN; FIBRONECTIN; GALUNISERTIB; KALININ; LY 2109761; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY D10; PROTEIN TYROSINE KINASE INHIBITOR; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG; VITRONECTIN; ANTINEOPLASTIC AGENT; CONNECTIVE TISSUE GROWTH FACTOR; CTGF PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; HOXD10 PROTEIN, HUMAN; LY-2157299; LY2109761; PROTEIN SERINE THREONINE KINASE; PYRAZOLE DERIVATIVE; PYRROLE DERIVATIVE; QUINOLINE DERIVATIVE; SMAD2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INHIBITION KINETICS; LIVER CELL CARCINOMA; MALE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CARCINOMA, HEPATOCELLULAR; DRUG EFFECTS; HEP-G2 CELL LINE; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CONNECTIVE TISSUE GROWTH FACTOR; FEMALE; HEP G2 CELLS; HOMEODOMAIN PROTEINS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; PYRROLES; QUINOLINES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84879528782     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/annotation/c943a596-3965-4a5b-a27c-55c16685ea32     Document Type: Erratum

References (24)

1. Parkin DM, Bray F, Ferlay J, Pisani P, (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
2. de Lope CR, Tremosini S, Forner A, Reig M, Bruix J, (2012) Management of HCC. J Hepatol 56Suppl 1: S75-S87 S0168-8278(12)60009-9 [pii];10.1016/S0168-8278(12)60009-9 [doi].
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
4. Iavarone M, Cabibbo G, Piscaglia F, Zavaglia C, Grieco A, et al. (2011) Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 54: 2055-2063 10.1002/hep.24644 [doi].
5. Akhurst RJ, Derynck R (2001) TGF-beta signaling in cancer-a double-edged sword. Trends Cell Biol 11: S44-S51. S0962-8924(01)02130-4 [pii].
6. Colombo M, (1999) Natural history and pathogenesis of hepatitis C virus related hepatocellular carcinoma. J Hepatol 31Suppl 1: 25-30.
7. Bissell MJ, Radisky D, (2001) Putting tumours in context. Nat Rev Cancer 1: 46-54.
8. Ito N, Kawata S, Tamura S, Takaishi K, Shirai Y, et al. (1991) Elevated levels of transforming growth factor beta messenger RNA and its polypeptide in human hepatocellular carcinoma. Cancer Res 51: 4080-4083.
9. Shirai Y, Kawata S, Tamura S, Ito N, Tsushima H, et al. (1994) Plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases. Cancer 73: 2275-2279.
10. Giannelli G, Mazzocca A, Fransvea E, Lahn M, Antonaci S, (2011) Inhibiting TGF-beta signaling in hepatocellular carcinoma. Biochim Biophys Acta 1815: 214-223 S0304-419X(10)00080-6 [pii];10.1016/j.bbcan.2010.11.004 [doi].
11. Mamiya T, Yamazaki K, Masugi Y, Mori T, Effendi K, et al. (2010) Reduced transforming growth factor-beta receptor II expression in hepatocellular carcinoma correlates with intrahepatic metastasis. Lab Invest 90: 1339-1345 labinvest2010105 [pii];10.1038/labinvest.2010.105 [doi].
12. Fransvea E, Angelotti U, Antonaci S, Giannelli G, (2008) Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology 47: 1557-1566.
13. Fransvea E, Mazzocca A, Antonaci S, Giannelli G, (2009) Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma. Hepatology 49: 839-850.
14. Jonas S, Bechstein WO, Steinmuller T, Herrmann M, Radke C, et al. (2001) Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 33: 1080-1086.
15. Giannelli G, Fransvea E, Marinosci F, Bergamini C, Colucci S, et al. (2002) Transforming growth factor-beta1 triggers hepatocellular carcinoma invasiveness via alpha3beta1 integrin. Am J Pathol 161: 183-193.
16. Sumie S, Kuromatsu R, Okuda K, Ando E, Takata A, et al. (2008) Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol 15: 1375-1382.
17. Mazzocca A, Fransvea E, Lavezzari G, Antonaci S, Giannelli G, (2009) Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation. Hepatology 50: 1140-1151.
18. Abreu JG, Ketpura NI, Reversade B, De Robertis EM, (2002) Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol 4: 599-604.
19. Kalluri R, Zeisberg M, (2006) Fibroblasts in cancer. Nat Rev Cancer 6: 392-401.
20. Mazzocca A, Fransvea E, Dituri F, Lupo L, Antonaci S, et al. (2010) Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma. Hepatology 51: 523-534.
21. Zhong Z, Carroll KD, Policarpio D, Osborn C, Gregory M, et al. (2010) Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells. Clin Cancer Res 16: 1191-1205 1078-0432.CCR-09-1634 [pii];10.1158/1078-0432.CCR-09-1634 [doi].
22. Bergamini C, Sgarra C, Trerotoli P, Lupo L, Azzariti A, et al. (2007) Laminin-5 stimulates hepatocellular carcinoma growth through a different function of alpha6beta4 and alpha3beta1 integrins. Hepatology 46: 1801-1809.
23. Bissell DM, (2001) Chronic liver injury, TGF-beta, and cancer. Exp Mol Med 33: 179-190.
24. Lencioni R, Llovet JM, (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30: 52-60 10.1055/s-0030-1247132 [doi].